HOME >> BIOLOGY >> NEWS
Anticancer drug reveals alternate means of inducing cell suicide

Derivatives of the COX-2 inhibitor celecoxib can trigger cancer cell suicide, or apoptosis, but not necessarily through the recognized means of blocking COX-2 enzyme activity, a new study concludes. By separating COX-2 activity from apoptosis, researchers have a starting point for designing new classes of anticancer drugs, write Xueqin Song, Ching-Shih Chen, Ph.D., Ohio State University, and their coworkers in the April 17 issue of the Journal of the National Cancer Institute.

Celecoxib, an anti-inflammation pill for arthritis, is being studied for its potential in preventing and treating certain cancers. In a large percentage of tumors, the COX-2 enzyme is elevated, say Ernest T. Hawk, M.D., M.P.H., of the National Cancer Institute, and his coworkers in an accompanying editorial. They point out that past studies have shown that decreasing levels of COX-2 can suppress the growth of tumors. However, it has been unclear whether celecoxibs anticancer effects depend on COX-2 inhibition alone.

To find out, Chen and his coworkers created prostate cancer cells lacking the COX-2 enzyme. In contrast to the effects of COX-2 inhibitors such as celecoxib, which induce cell death, cells that lacked COX-2 remained alive. Exposure of these cells lacking COX-2 to various COX-2 inhibitors did lead to cell death. Whats more, derivatives of celecoxib that did not block COX-2 activity also caused cell death.

The authors note that these events were associated not with levels of COX-2 but with decreased phosphorylation of Akt and ERK2 proteins. This mode of action differs from that of conventional anticancer drugs, they point out.

In the accompanying editorial, Hawk and his colleagues note that celecoxib is being tested for the treatment and prevention of colon cancer and that newer generations of COX-2 inhibitors could prove to be safer and more effective.

However, they point out that the current findings are based on concentrations of c
'"/>

Contact: Linda Wang
jncinews@oup-usa.org
301-841-1287
Journal of the National Cancer Institute
16-Apr-2002


Page: 1 2

Related biology news :

1. Anticancer drug zebularine specifically targets tumor cells
2. The Bodys Anticancer Weaponry Backfires In Old Age
3. Enzymes "Magic" May Hold Key to Anticancer and Antimicrobial Drugs
4. Hidden diversity: DNA barcoding reveals a common butterfly is actually 10 different species
5. Brown research reveals key insight into memory-making
6. Study reveals why eyes in some paintings seem to follow viewers
7. New dye directly reveals activated proteins in living cells
8. Study reveals first genetic step necessary for prostate cancer growth
9. Study of flu patients reveals virus outsmarting key drug
10. Study in Science reveals recreational fishing takes big bite of ocean catch
11. Plumbing trees plumbing reveals their engineering skill

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/20/2016)... 20, 2016 A market that just keeps ... from the explosion in genomics knowledge. Learn all about ... A range of dynamic trends are pushing market growth ... medicine - pharmacogenomics - pathogen evolution - next generation ... - greater understanding of the role of genetic material ...
(Date:1/18/2016)... SAN JOSE, Calif. , Jan. 18, 2016 ... storage security software that simplifies the use and ... a technology and go-to-market partnership with American Cyber.  ... "American Cyber brings extensive experience leading transformational C4ISR ... missions implementing and integrating the latest proven technology ...
(Date:1/13/2016)... , January 13, 2016 ... the addition of the  "India Biometrics ... & Forecast (2015-2020)"  report to ... ) has announced the addition of ... Market - Estimation & Forecast (2015-2020)" ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... N.J. , Feb. 4, 2016  CytoSorbents ... immunotherapy leader commercializing its flagship CytoSorb® blood filter ... surgery patients around the world, announced that CEO ... present at the Source Capital Group,s 2016 Disruptive ... update on the company.  Conference ...
(Date:2/4/2016)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... held February 8-9, 2016, at the Waldorf Astoria New ... Healthcare Conference, taking place in New York ... Sapirstein , Chief Executive Officer of ContraVir, will provide ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... leading supplier of Semantic Graph Database technology has been recognized As “ Best ... by Corporate America Magazine. , “At Corporate America, it’s our priority to showcase ...
(Date:2/3/2016)... 2016   ViaCyte, Inc ., a leading, ... stem cell-derived islet replacement therapy for the treatment ... announced that ViaCyte and Janssen Biotech, Inc., one ... Johnson, have agreed to consolidate the assets of ... provides ViaCyte with an exclusive license to all ...
Breaking Biology Technology:
Cached News: